GW&K Investment Management Trims AbbVie Stake

Institutional investor reduces holdings in pharmaceutical giant by 1.6%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

GW&K Investment Management LLC, an institutional investor, reduced its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 1.6% during the third quarter, according to a recent SEC filing. The firm now owns 375,778 shares of the company's stock, valued at $87,008,000.

Why it matters

AbbVie is a major pharmaceutical company with a diverse portfolio of drugs, including blockbuster immunology and oncology treatments. Changes in institutional ownership can provide insights into investor sentiment and market trends around the stock.

The details

According to the filing, GW&K Investment Management sold 6,207 shares of AbbVie during the third quarter. The firm now holds a 0.8% stake in the company, making it AbbVie's 23rd largest institutional investor.

  • The share sale occurred during the third quarter of the fiscal year.

The players

GW&K Investment Management LLC

An institutional investment management firm that owned 375,778 shares of AbbVie as of its most recent SEC filing.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across several therapeutic areas, including immunology, oncology, neuroscience, and women's health.

Got photos? Submit your photos here. ›

The takeaway

This modest reduction in GW&K Investment Management's AbbVie holdings suggests the firm may be taking a more cautious stance on the stock, though the overall investment remains substantial. Investors will likely continue to monitor institutional activity around AbbVie as an indicator of broader market sentiment towards the company and its pipeline.